Previously, our group applied a genome wide CRISPR-dCas9 screen to identify acquired resistance mechanisms to the CDK4/6 inhibitor Palbocicib in bladder cancer cell lines [32]. The gene discussed is CDK4; the disease is urinary bladder cancer.